Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial.
- DOI
- 10.1016/s2213-8587(25)00096-8
- Published
- 2025-06-04
- Container
- Lancet Diabetes Endocrinol
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s2213-8587-25-00096-8,
title = {Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial.},
author = {Mathieu C and Giorgino F and Kim SG and Larsen JH and Philis-Tsimikas A and Ramachandran A and Pagliaro Rocha TM and Shankarappa VB and Terauchi Y and Ji L.},
year = {2025},
journal = {Lancet Diabetes Endocrinol},
doi = {10.1016/s2213-8587(25)00096-8},
url = {https://doi.org/10.1016/s2213-8587(25)00096-8}
}RIS
TY - JOUR TI - Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial. AU - Mathieu C AU - Giorgino F AU - Kim SG AU - Larsen JH AU - Philis-Tsimikas A AU - Ramachandran A AU - Pagliaro Rocha TM AU - Shankarappa VB AU - Terauchi Y AU - Ji L. PY - 2025 JO - Lancet Diabetes Endocrinol DO - 10.1016/s2213-8587(25)00096-8 UR - https://doi.org/10.1016/s2213-8587(25)00096-8 ER -
APA
C, M., F, G., SG, K., JH, L., A, P., A, R., TM, P. R., VB, S., Y, T., & L., J. (2025). Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial.. Lancet Diabetes Endocrinol. https://doi.org/10.1016/s2213-8587(25)00096-8
Source records
- europe-pmc · retrieved 2026-09-27T08:54:07.045Z